Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?

Johnson Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of heart pump maker Abiomed for a whopping $16.6 billion. And recently, J announced yet another major deal: It is acquiring Shockwave Medical (NASDAQ: SWAV) for $13.1 billion.

What does this mean for the company, and does this move make Johnson Johnson an attractive option for growth investors?

Johnson Johnson's two key segments are medtech and innovative medicines. While the company invests in research and development to build out its pharma business, one way it has been bolstering its medtech division has been through acquisitions.

Continue reading

Source Fool.com